24-week randomized, double-blind, double-dummy, parallel trial to evaluate efficacy and safety of linagliptin vs placebo as add-on to empagliflozin and metformin in patients with type 2 diabetes
Latest Information Update: 17 Nov 2017
At a glance
- Drugs Empagliflozin (Primary) ; Linagliptin (Primary) ; Metformin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 17 Nov 2017 New trial record